Fragile X Syndrome Market Hope on the Horizon Targeting the Cause: Growth Prospects 2024-2031

Fragile X Syndrome Market worth $ 37.8 Million by 2030 - Exclusive Report by InsightAce Analytic

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Fragile X Syndrome Market- by Product Pipeline (Phase I, Phase II and Phase III), Trends, Industry Competition Analysis, Revenue and Forecast To 2030."

Get a free sample copy of the report: https://www.insightaceanalytic.com/request-sample/1065

According to the latest research by InsightAce Analytic, the global Fragile X Syndrome market is valued at US$ 21.5 Million in 2021, and it is expected to reach US$ 37.8 Million by 2030, with a CAGR of 7.3% during a forecast period of 2024-2031.

Fragile X Syndrome: A Genetic Disorder Affecting Development
Fragile X syndrome is a genetic disorder that primarily affects cognitive function and causes learning difficulties. Men are more severely affected by this condition than women. While roughly one-third of women with Fragile X syndrome experience intellectual disability, the majority of men have mild to severe intellectual disability.

Children with Fragile X syndrome typically experience delayed speech and language development by the age of two. They may also exhibit behavioral issues such as hyperactivity, fidgeting, impulsive actions, and difficulty focusing or paying attention. Additionally, around one-third of individuals with Fragile X syndrome display characteristics of autism spectrum disorder, impacting their social interaction and communication skills.

The global market is driven by the higher prevalence of males than females and the disease's recurrence from generation to generation. The market growth is further supported by the presence of a robust pipeline, which causes pharmaceutical and biotechnology companies to concentrate more on performing research projects to treat the condition favorably. The reasons driving the growth of this market are emerging markets and significant investments in R&D.

Additionally, the market is growing as a result of an increase in genetic mutation syndrome instances and an increase in the bad lifestyles of pregnant women (including consuming alcohol and smoking). Four pipeline agents' entries will fuel the FXS market's enormous growth. Notably, the most significant drivers of growth are the sales of pricy pipeline agents like zatolmilast, Zygel, and trofinetide. However, the global Fragile X Illness (FXS) therapy market may be hampered by a lack of knowledge about the syndrome and expensive treatment in underdeveloped nations.

North America is anticipated to be the major contributor to the Fragile X Syndrome market over the forecast years. It is due to the increasing number of collaborations between multiple small and medium-sized businesses and numerous corporations to develop cost-effective and high-quality medications that most people can buy. Furthermore, the rising prevalence of neurodegenerative diseases, as well as the increasing demand for effective treatments for gene abnormalities through research, diagnostics, and synthetic biology, has fueled the regional market expansion. In addition, the Asia Pacific

Fragile X Syndrome market is expected to grow significantly during the forecast period due to significant investments made by biotechnology and pharmaceutical companies, enhanced healthcare institutions, early availability of approved medications, rise in income per capita, and accessibility of state-of-the-art research facilities throughout the country in the region.

Major market players operating in the Fragile X Syndrome market include
Marinus pharmaceuticals, Kareus Therapeutics, Ovid therapeutics, Bellus Health Inc., Neuren pharmaceuticals, Anavex Life Sciences Corp., AMO pharmaceuticals, Eli Lilly & Company, and Zynerba Pharmaceuticals, Inc.

Recent collaborations and agreements in the market:
• In March 2022, the European Commission classified Zygel, a (transdermal gel candidate from Zynerba Pharmaceuticals for treating behavioural issues in people with fragile X syndrome, as an orphan medicine.

• In February 2022, Ovid and Healx decided to enter into an agreement signed for an exclusive gaboxadol licence (OV101). Healx was given the option by Ovid to create and market gaboxadol alone (OV101). In addition to treatment for other conditions, Healx has declared that it will investigate the chemical as a potential component of a combination treatment for Fragile X syndrome.

• In December 2021, Nova Mentis Life Science and Mycrodose Therapeutics announced that the combination of NOVA's psilocybin-based pharmaceutical development programme and Mycrodose's transdermal solution for fragile X syndrome has been completed successfully.

Curious about this latest version of the report? Obtain Report Details @ https://www.insightaceanalytic.com/enquiry-before-buying/1065

Market Segments
Global Fragile X Syndrome Market, by Product Pipeline, 2022-2030 (Value US$ Mn)
• Phase I
• Phase II
• Phase III

Global Fragile X Syndrome Market, by Region, 2022-2030 (Value US$ Mn)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

North America Fragile X Syndrome Market, by Country, 2022-2030 (Value US$ Mn)
• U.S.
• Canada

Europe Fragile X Syndrome Market, by Country, 2022-2030 (Value US$ Mn)
• Germany
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific Fragile X Syndrome Market, by Country, 2022-2030 (Value US$ Mn)
• India
• China
• Japan
• South Korea
• Australia & New Zealand

Latin America Fragile X Syndrome Market, by Country, 2022-2030 (Value US$ Mn)
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa Fragile X Syndrome Market, by Country, 2022-2030 (Value US$ Mn)
• GCC Countries
• South Africa
• Rest of Middle East & Africa

Why should buy this report:
 To receive a comprehensive analysis of the prospects for the global Fragile X Syndrome market
 To receive an industry overview and future trends of the Fragile X Syndrome market
 To analyze the Fragile X Syndrome market drivers and challenges
 To get information on the Fragile X Syndrome market value (US$Mn) forecast to 2030
 Significant investments, mergers & acquisitions in the Fragile X Syndrome market industry

For More Information @ https://www.insightaceanalytic.com/customisation/1065

Contact Us:
InsightAce Analytic Pvt. Ltd.
Tel.: +1 718 593 4405
Email: info@insightaceanalytic.com
Site Visit: www.insightaceanalytic.com
Follow Us on LinkedIn @ bit.ly/2tBXsgS
Follow Us On Facebook @ bit.ly/2H9jnDZ

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions.
Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses.
We help clients gain a competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets, and repositioning products.
Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

This release was published on openPR.